At 13.9% CAGR, Asia Pacific Traumatic Brain Injury Diagnostics Equipment Market Projected to be Worth US$ 1,030.47 Million by 2030, says Business Market Insights

According to Business Market Insights’ research, the Asia Pacific traumatic brain injury diagnostics equipment market was valued at US$ 362.82 million in 2022 and is expected to reach US$ 1,030.47 million by 2030, registering a CAGR of 13.9% from 2022 to 2030. Quick and effective diagnosis for  TBI patients and growing use of MRI over CT to limit inpatient mortality and marginally reduce diagnostic cost are among the critical factors attributed to drive the Asia Pacific traumatic brain injury diagnostics equipment market growth.

The main hurdle for the recovery of TBI is that it is often left undiagnosed or misdiagnosed. In the past, concussions and TBIs were diagnosed through diagnostic equipment such as computed tomography (CT) scans and other neurological examinations. However, the use of CT can increase the risk of cancer due to radiation exposure. Therefore, a prompt and accurate brain injury diagnosis is of utmost importance to address mild to severe brain injuries. In October 2023, the Biomedical Advanced Research and Development Authority (BARDA) announced a collaboration with GE Healthcare to develop a novel artificial intelligence (AI)-augmented ultrasound technology in order to promote rapid diagnosis of traumatic injuries. Also, BARDA will support GE Healthcare in the development of a portable ultrasound system to enhance disaster preparedness with fast response for trauma care during mass casualty incidents.

On the contrary, adverse effects of contrast medium/agent hamper the growth of Asia Pacific traumatic brain injury diagnostics equipment market.

Based on techniques, the Asia Pacific traumatic brain injury diagnostics equipment market is segmented into non-invasive, invasive, and combination techniques. The invasive segment held 50.1% market share in 2022, amassing US$ 181.68 million. It is projected to garner US$ 502.22 million by 2030 to register 13.6% CAGR during 2022–2030. Furthermore, the non-invasive segment is subcategorized into electroencephalography (EEG), brain–computer interface (BCI), eye tracking and near-infrared spectroscopy (NIRS), magnetic resonance imaging (MRI), magnetoencephalography (MEG), transcranial magnetic stimulation (TMS), cerebral metabolic rate of oxygen (CMRO2), intracranial pressure, and others .Additionally, invasive segment is subsegmented into cerebral perfusion pressure (CPP) and pressure reactivity index (PRx), partial brain tissue oxygen pressure (PbtO2), cerebral microdialysis (CMD), intracranial pressure, and others.

In terms of device, the Asia Pacific traumatic brain injury diagnostics equipment market is bifurcated into imaging devices and monitoring devices. The imaging devices segment held 80.9% share of Asia Pacific traumatic brain injury diagnostics equipment market in 2022, amassing US$ 293.53 million. It is anticipated to garner US$ 818.02 million by 2030 to expand at 13.7% CAGR during 2022–2030.

By end user, the Asia Pacific traumatic brain injury diagnostics equipment market is divided into hospitals and clinics, diagnostic centers, and others. The hospitals and clinics segment held 54.1% share of Asia Pacific traumatic brain injury diagnostics equipment market in 2022, amassing US$ 196.38 million. It is projected to garner US$ 551.63 million by 2030 to expand at 13.8% CAGR from 2022 to 2030.

Based on country, the Asia Pacific traumatic brain injury diagnostics equipment market is categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 29.2% share of Asia Pacific traumatic brain injury diagnostics equipment market in 2022. It was assessed at US$ 105.83 million in 2022 and is likely to hit US$ 293.17 million by 2030, registering a CAGR of 13.6% during 2022–2030.

Key players operating in the Asia Pacific traumatic brain injury diagnostics equipment market are GE HealthCare Technologies Inc, Elekta AB, Integra LifeSciences Holdings Corp, Natus Medical Inc, Raumedic AG, Soterix Medical Inc, Medtronic Plc, Compumedics Ltd, and Sense Diagnostics Inc, among others.

• In April 2022, NeuraSignal Inc announced the upgradation of its NovaSignal Platform. A new feature called Morphology has been added to the platform, providing advanced analysis of cerebral waveforms. The new feature enabled faster and easier assessment of patients with suspected neurological conditions such as stroke.
• In January 2024, Compumedics Ltd revealed that Tsinghua and Tianjin Universities in China had placed additional MEG orders. Beijing Fistar, company’s' longstanding Chinese distributor and partner, is handling these sales. In 2025, the MEG systems will be delivered to both locations together with a plethora of accessories such as PCs, stimulators, simultaneous EEG, and CURRY neuroimaging software. Two single-helmet MEG systems and a dual-helmet MEG system are the subject of one order each. Both will be set up for hyperscanning, which is the simultaneous measurement of two subjects to examine their interactions.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com